EGRX Eagle Pharmaceuticals Inc.

Final Reminder: Eagle Pharmaceuticals to Host 2016 Investor Day in New York City

Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (NASDAQ:EGRX) today issued a final reminder regarding its previously announced 2016 Investor Day. The event will be held on Friday, November 11, 2016 at the Pierre Hotel located at 2 East 61st Street, New York City. The meeting, which also will be webcast live, will begin promptly at 8:00 a.m. Eastern Standard Time (EST) and end at approximately 11:30 a.m. EST. Breakfast and registration will begin at 7:00 a.m.

Institutional investors and analysts who have not already registered and are interested in attending the event can RSVP to Lisa Wilson, Investor Relations for Eagle Pharmaceuticals, either via telephone at 1-212-452-2793 or e-mail at [email protected].

Institutional investors and analysts unable to attend in person are invited to listen to the investor meeting via a live audio webcast which can be viewed on the Investor Relations section of the Company's website at www.eagleus.com.

A webcast replay will be available for on-demand listening shortly after the completion of the event for 90 days, at the aforementioned section, also at www.eagleus.com.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
01/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Right...

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stoc...

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results ...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quart...

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at . About Eagle Pharmaceuticals, Inc.Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarte...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at . About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meani...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Au...

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time. The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on Au...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch